Drug interactions
Encorafenib + Ticlopidine
Severity: Minor
Encorafenib and Ticlopidine: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ticlopidine is not a sensitive CYP3A4 substrate for clinical effect, but it does depend partly on hepatic activation, and encorafenib's mixed CYP3A4 inhibition and induction could change ticlopidine exposure unpredictably. Clinical significance is uncertain.
What this interaction means in plain words
Encorafenib and Ticlopidine have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Encorafenib belongs to Oncology; Ticlopidine belongs to Cardiovascular.
Why it happens
Encorafenib both inhibits and induces CYP3A4, which may variably alter ticlopidine metabolism.
What to do
No routine change is needed; monitor platelet response and blood counts per ticlopidine standards.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Ticlopidine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ticlopidine
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Ticlopidine?
MediHelp rates the interaction as minor. Encorafenib and Ticlopidine have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Ticlopidine is not a sensitive CYP3A4 substrate for clinical effect, but it does depend partly on hepatic activation, and encorafenib's mixed CYP3A4 inhibition and induction could change ticlopidine exposure unpredictably. Clinical significance is uncertain.
How serious is the interaction between Encorafenib and Ticlopidine?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine change is needed; monitor platelet response and blood counts per ticlopidine standards.
What other medicines interact with Ticlopidine?
MediHelp also lists interactions of Ticlopidine with, for example, Mavacamten, Abrocitinib, Acetylsalicylic acid. The full list is on the Ticlopidine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
